Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the treatment of CKD and AKI. This new biomarker data is in addition to the previously-announced significant reduction in new collagen deposition (57%) observed in a preclinical fibrosis model and provides the potential for new intellectual property.

Reduction in new collagen deposition (fibrosis) helps maintain kidney function. Fibrosis or scarring, results in loss of normal kidney function. Loss of normal kidney function causes the build-up of toxic materials which leads to further deleterious health effects, propagation of chronic disease, and ultimately, death.

During the first half of 2023 Revelation plans to initiate a Phase 1a clinical study comprising 5 cohorts of single ascending doses and a 6^th cohort of multiple doses of REVTx-300 to investigate safety and drug activity. Revelation plans to initiate a Phase 1b clinical study in patients undergoing elective cardiac surgery in the second half of 2023.

“Modulation of the innate immune response has tremendous potential to treat a wide variety of inflammatory diseases,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to working with our scientific advisors to advance our understanding of the complex biology of PHAD for the treatment of inflammatory disease and infection and initiating clinical studies in 2023.”

Revelation originally announced on October 25, 2022 positive results from the preclinical model of acute kidney injury and chronic kidney disease. Additional analysis found that treatment with REVTx-300 significantly reduced new collagen deposition (fibrosis) in the renal cortex in a dose dependent manner in the medium and high dose groups (42.1% reduction (p <0.05) and 56.7% (p < 0.05), respectively). The reduction in new collagen formation was calculated for each treatment group vs the unilateral ureteral obstruction (UUO) control group after correction for the normal collagen levels observed in the sham control.

In addition to the reduction in new collagen deposition, treatment with REVTx-300 had no significant effect on body weight or kidney weight when compared to the UUO control group animals. REVTx-300 had minimal impact on hydroxyproline content in the renal cortex in a non-dose dependent manner when compared to the UUO control group.

The UUO model is appropriate for studying the anti-inflammatory and anti-fibrotic effects of potential new therapies for acute and chronic kidney disease as complete ureteral obstruction of one kidney results in significant inflammation and subsequent fibrosis of the affected kidney over a 7-day period.

About REVTx-300

REVTx-300 is our proprietary formulation for systemic administration of PHAD and is being developed as a potential therapy for the treatment of acute and chronic organ disease including chronic kidney disease (CKD), acute kidney injury (AKI), myocarditis, and nonalcoholic steatohepatitis (NASH). Chronic disease of an organ, due to chronic inflammation and subsequent fibrosis, follows a pattern of perpetual and ongoing destruction of living functional cells and subsequent replacement by the non-functional protein, collagen, resulting in fibrosis (scar tissue). The establishment of fibrosis and subsequent death of the organ is driven by chronic inflammatory processes and reactive oxygen species mediated by the innate immune response. We believe redirection of the innate immune response with REVTx-300 from a pro-inflammatory state to an anti-inflammatory (protective) state may rebalance the innate immune response to slow down or halt the progressive destruction and scarring of organ tissue, allowing the healing process to take place.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx‑100 is being developed as a prevention and treatment of infection. REVTx‑200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI, myocarditis, and NASH. REVTx‑99b is being developed as a treatment for food allergies. REVDx‑501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, eliminating the need for specialized instrumentation.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the clinical utility of an increase in intranasal cytokine levels as a biomarker of viral infections; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the potential impact that COVID‑19 may have on Revelation’s suppliers, vendors, regulatory agencies, employees and the global economy as a whole; the ability of Revelation to maintain the listing of its securities on NASDAQ; investor sentiment relating to SPAC related going public transactions; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005121/en/